Immunotherapy News and Research

Latest Immunotherapy News and Research

Researchers develop possible new method for treating pancreatic cancer

A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers.

22 Dec 2013

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck, known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.

18 Dec 2013

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.

18 Dec 2013

Probiotics could be next potential weapon to fight malnutrition

The University of British Columbia public affairs office has published today a story on probiotic intervention as the next potential weapon against malnutrition.

17 Dec 2013

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.

17 Dec 2013

OncoSec Medical reports positive interim data from OMS-I100 Phase 2 trial for metastatic melanoma

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced positive interim data from its ongoing Phase 2 trial of OMS-I100 in the treatment of metastatic melanoma. The results were presented by principal investigator Adil Daud, MD, at the Advances in Cancer Immunotherapy meeting at the University of California San Francisco.

16 Dec 2013

MD Anderson researcher earns Breakthrough Prize in Life Sciences

Basic science research that exposed vital details of cancer's defense against the immune system, revealing an entirely new way to combat these diseases, has earned Jim Allison, Ph.D., a Breakthrough Prize in Life Sciences.

14 Dec 2013

ESMO’s position paper highlights role of oncologists toward quality cancer care

Medical oncologists have a vital role to play in cancer care, particularly as treatments become ever more complex, a new position statement from the European Society for Medical Oncology says.

13 Dec 2013

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers.

13 Dec 2013

Immunocellular Therapeutics reports positive results from ICT-107 Phase II study in glioblastoma patients

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.

12 Dec 2013

Budget cuts, years-long flat funding can delay research into effective treatments for cancer

Research advances that have come to fruition over the past year demonstrate extraordinary progress in the fight against cancer, according to a new report released today by the American Society of Clinical Oncology. The report stresses, however, that recent budget cuts and years-long flat funding can only delay efforts to translate research into effective treatments for millions of individuals with cancer.

11 Dec 2013

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children's Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.

9 Dec 2013

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

9 Dec 2013

Scientists target protein-detection approach to systematically measure human repertoire of proteins

An international team of scientists led by Fred Hutchinson Cancer Research Center cancer proteomics expert Amanda Paulovich, M.D., has demonstrated the feasibility of large-scale, standardized protein measurements, which are necessary for validation of disease biomarkers and drug targets.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.

5 Dec 2013

New method for counting tumor-fighting cells to predict ovarian cancer

One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.

5 Dec 2013

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

Better understanding of cancer evolution could help in early detection of cancers

A new appreciation of how cancer cells evolve could help scientists design better screening methods to catch cancer before it advances.

4 Dec 2013

Immunotherapy News and Research

Latest Immunotherapy News and Research

Researchers develop possible new method for treating pancreatic cancer

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Probiotics could be next potential weapon to fight malnutrition

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

OncoSec Medical reports positive interim data from OMS-I100 Phase 2 trial for metastatic melanoma

MD Anderson researcher earns Breakthrough Prize in Life Sciences

ESMO’s position paper highlights role of oncologists toward quality cancer care

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Immunocellular Therapeutics reports positive results from ICT-107 Phase II study in glioblastoma patients

Budget cuts, years-long flat funding can delay research into effective treatments for cancer

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Scientists target protein-detection approach to systematically measure human repertoire of proteins

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

New method for counting tumor-fighting cells to predict ovarian cancer

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Better understanding of cancer evolution could help in early detection of cancers

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Immunotherapy News and Research

Latest Immunotherapy News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in